9 meters biopharma, inc. (INNT)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Net sales

-

-

-

4,065

8,266

11,343

Cost of goods sold

-

-

-

3,329

7,840

11,109

Gross profit (loss)

-

-

-

736

426

234

Operating expenses:
Research and development

13,715

7,559

4,007

270

333

542

Selling and marketing

-

-

-

2,425

2,928

3,722

General and administrative

10,566

10,664

7,161

3,984

3,625

2,646

Warrant inducement expense

1,265

0

-

-

-

-

Trademark impairment

-

-

-

0

-

-

Total operating expenses

25,548

18,224

11,169

6,679

6,886

6,910

Loss from operations

25,548

18,224

11,169

-5,943

-6,460

-6,676

Other income (expense):
Interest income

185

163

0

-

-

-

Interest expense

1,825

6,152

436

825

1,381

1,661

Gain of settlement of customer refund

-

-

-

0

-

-

Gain (Loss) on Extinguishment of Debt

-1,049

0

-

0

-

-

Change in fair value of derivative liability and extinguishment of derivative liability

1,243

50

0

-

-

-

Fair Value Adjustment of Warrants

54

0

-

-

-

-

Gain on debt conversion

-

-

-

557

0

-

Total other income (expense), net

-1,500

-5,938

-436

-268

-

-

Debt conversion expense

-

-

-

-

898

2,707

Total other expenses

-

-

-

-

-2,279

-4,368

Loss before income taxes

-27,048

-24,162

-11,605

-6,211

-8,739

-11,044

Benefit from income taxes

0

0

0

2

2

13

Net Income (Loss) Attributable to Parent

-27,048

-24,162

-11,605

-6,213

-8,741

-11,057

Warrant tender offer inducement charge

-

-

-

0

-

-

Net loss attributable to common shareholders

-

-

-

-6,213

-

-

Net loss per common share, basic and diluted (in usd per share)

-0.81

-0.98

-0.98

-11.26

2.65

3.95

Weighted-average common shares, basic and diluted (in shares)

33,328

24,762

11,888

552

3,294

2,800